Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension
C. B. Camras, R. A. Schumer, A. Marsk, J. S. Lustgarten, J. B. Serle, J. Stjernschantz, L. Z. Bito and S. M. Podos
Department of Ophthalmology, Mt Sinai School of Medicine, New York, NY.
In a randomized, double-masked, parallel study, one drop of 0.003% (1
microgram; n = 9) or 0.01% (3 micrograms; n = 10) PhXA34, a new
phenyl-substituted prostaglandin F2 alpha analogue
(13,14-dihydro-15[R,S]-17-phenyl-18,19,20-trinor-prostaglandin F2
alpha-1-isopropyl ester), or its vehicle (n = 10) was applied topically
twice daily for 6 days to one eye in each of 29 patients with ocular
hypertension. Compared with either baseline, contralateral, or vehicle
control values, PhXA34 caused a significant (P < .001) dose-dependent
reduction of intraocular pressure. The reduction lasted at least 12 hours
after each drop and 24 to 48 hours after the last drop, with a significant
(P < .0001) mean +/- SEM reduction of as much as 10 +/- 1 mm Hg (40%).
Conjunctival hyperemia was not produced by 0.003% PhXA34, but was noted in
some eyes treated with 0.01% PhXA34, and after repeated tonometry with
either concentration. The prostaglandin analogue did not produce clinically
obvious miosis, anterior chamber flare or cellular response, or any
subjective adverse effects. PhXA34 is a potent, effective, and
well-tolerated ocular hypotensive agent based on our results in this small,
short-term study. Its potential as a new drug for glaucoma therapy warrants
further investigation in long-term, larger studies.
